VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

VERTEX PHARMACEUTICALS INC / MA

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$501.95+2.21 (+0.44%)

Close on Oct 19, 2026

Market cap: $128.10B
P/E (TTM): 29.2
Dividend yield: –

VERTEX PHARMACEUTICALS INC / MA balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Cash & Equivalents	5,085	4,570	10,369	10,504	6,795	5,988	3,109	2,650	1,665	1,184	715	625	569	489	475	243	447	389	356
Short-Term Investments	1,523	1,546	849	275	730	671	699	518	423	–	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	6,608	6,116	11,218	10,779	7,525	6,659	3,808	3,168	2,089	1,184	715	625	569	489	475	243	447	389	356
Receivables	2,053	1,609	1,563	1,442	1,137	885	634	410	281	200	174	76	86	143	183	13	9.60	–	–
Inventory	1,687	1,205	739	461	353	281	168	124	112	78	57	31	14	30	112	–	–	–	–
Prepaid Expenses & Other	853	666	624	554	546	308	214	141	167	71	55	44	24	25	15	13	–	–	–
Other Current Assets	111	76	84	74	59	80	–	62	76	34	13	7.00	0.52	–	–	–	–	–	–
Total Current Assets	11,201	9,596	14,144	13,235	9,561	8,133	4,823	3,843	2,649	1,832	1,407	1,547	1,589	1,590	1,331	1,057	1,307	–	–
Property, Plant & Equipment	1,520	1,228	1,159	1,108	1,094	959	745	812	789	698	698	716	697	434	133	72	62	–	–
Gross Property, Plant & Equipment	–	–	–	–	–	–	–	1,263	1,222	1,086	1,034	994	1,005	730	404	320	284	–	–
Accumulated Depreciation	–	–	–	–	–	–	–	-451	-432	-388	-336	-278	-308	-297	-271	-247	-222	–	–
Construction in Progress	–	–	–	–	–	–	–	–	–	–	–	–	503	291	55	–	–	–	–
Long-Term Investments	5,712	5,108	2,498	112	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	1,563	1,357	294	347	330	326	88	62	–	–	–	–	–	–	–	–	–	–	–
Goodwill	1,088	1,088	1,088	1,088	1,002	1,002	1,002	50	50	50	50	40	31	31	31	26	26	–	–
Intangible Assets	424	826	840	604	400	400	400	0	–	–	–	–	–	–	–	–	–	–	–
Deferred Tax Assets	2,898	2,331	1,812	1,247	935	883	1,191	1,500	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	1,237	999	895	410	111	49	69	41	27	12	6.91	3.27	2.56	9.67	11	17	11	–	–
Total Assets	25,643	22,533	22,730	18,151	13,433	11,752	8,318	6,246	3,546	2,897	2,499	2,335	2,319	2,759	2,204	1,725	1,955	–	–
Accounts Payable	462	413	365	304	195	155	88	111	74	61	75	71	49	101	75	36	37	–	–
Accrued Expenses	2,971	2,789	2,655	2,127	1,679	1,405	1,117	959	444	315	306	210	271	265	243	134	119	–	–
Current Portion of Leases	77	87	33	49	33	11	12	–	–	–	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	103	161	100	123	211	104	72	43	–	6.88	31	10	11	2.18	12	–	–	–	–
Deferred Revenue (Current)	–	–	–	–	–	–	–	–	5.17	6.01	16	17	22	28	45	75	75	–	–
Other Current Liabilities	428	363	527	312	268	317	130	50	34	11	14	4.80	25	20	12	6.15	15	–	–
Total Current Liabilities	3,861	3,565	3,547	2,742	2,142	1,878	1,335	1,120	807	793	506	368	398	433	392	475	285	–	–
Long-Term Leases	1,847	1,544	349	380	377	351	84	65	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	1,924	1,632	382	428	411	361	96	65	–	–	–	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	–	–	–	–	–	–	–	0	6.34	134	110	15	0	280	244	160	160	–	–
Other Long-Term Liabilities	1,270	1,015	878	686	303	108	99	109	28	29	32	22	12	14	7.29	2.27	–	–	–
Total Liabilities	6,977	6,124	5,150	4,238	3,333	3,065	2,233	1,811	1,504	1,559	1,405	1,238	963	1,525	1,239	1,221	859	–	–
Preferred Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	–	0	–	–
Common Stock	2.50	2.60	2.60	2.60	2.50	2.60	2.59	2.55	2.51	2.45	2.43	2.39	2.32	2.15	2.07	2.02	1.98	–	–
Additional Paid-In Capital	5,119	6,672	7,450	7,387	6,881	7,894	7,938	7,421	7,157	6,507	6,198	5,777	5,321	4,519	4,201	3,947	3,785	–	–
Retained Earnings	13,560	9,607	10,142	6,523	3,201	859	-1,853	-2,989	-5,120	-5,374	-5,262	-4,705	-3,967	-3,522	-3,415	-3,444	-2,690	–	–
Comprehensive Income & Other	-16	128	-14	0.80	16	-69	-1.97	0.66	-12	21	1.82	0.92	-0.31	-0.55	-1.05	-1.07	-0.64	–	–
Shareholders' Equity	18,666	16,410	17,580	13,913	10,100	8,687	6,085	4,435	2,029	1,157	940	1,075	1,356	999	787	504	–	–	–
Noncontrolling Interest	–	–	–	–	–	–	–	0	14	182	154	21	0	197	142	–	–	–	–
Total Equity	18,666	16,410	17,580	13,913	10,100	8,687	6,085	4,435	2,042	1,338	1,094	1,096	1,356	1,196	928	504	1,096	239	271
Total Liabilities & Equity	25,643	22,533	22,730	18,151	13,433	11,752	8,318	6,246	3,546	2,897	2,499	2,335	2,319	2,759	2,204	1,725	1,955	–	–
Shares Outstanding(shares)	254	257	258	257	254	260	259	255	253	248	246	242	234	217	209	204	200	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 86.0%
Operating margin: 38.0%
Net margin: 35.0%
Return on equity, FY2025: 22.5%

Financial strength

Current ratio: 3.19
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 156.0%

Valuation

P/E ratio: 29.2
Price to sales: 10.18
Price to book: 6.33
Dividend yield: –